1. Pink Sheet

Did Sarepta Need To Tell Investors About Its Vyondys 53 Dispute Resolution Request?

 
• By Brenda Sandburg

Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.

Close up of girl's hand placing the last jigsaw puzzle piece with word Dispute Resolution
Sarepta did not publicly disclose that it made a formal dispute resolution request over Vyondys 53 complete response letter

Sarepta Therapeutics Inc. had not revealed that it submitted a formal dispute resolution request appealing the US Food and Drug Administration's complete response letter for Vyondys 53 (golodirsen) so the announcement that the agency had approved the Duchenne muscular disease drug was surprising news.

Companies must file a Form 8-K with the Securities and Exchange Commission to announce certain types of material events. So...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Compliance

More from Pink Sheet

EMA Explores Supporting Drug Development For High Unmet Need Disorder Scleroderma

 
• By Neena Brizmohun

While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.

EMA Nod For First MASH Drug Rezdiffra, Cell Therapy Zemcelpro And 11 Others

 
• By Eliza Slawther

Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.

BIO Notebook: Policy Uncertainty Constraining Dealmaking

 
• By Mandy Jackson and Joseph Haas

Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.